Literature DB >> 23499157

Sofosbuvir: the final nail in the coffin for hepatitis C?

Michael P Manns1, Markus Cornberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23499157     DOI： 10.1016/S1473-3099(13)70074-4

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  12 in total

1.  [Step-by-step toward the perfect hepatitis C treatment for all genotypes].

Authors:  M Cornberg; S Nitschmann
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

Review 2.  [New direct-acting antiviral agents for the treatment of chronic hepatitis C in 2014].

Authors:  M Cornberg; C Höner zu Siederdissen; B Maasoumy; M P Manns
Journal:  Internist (Berl)       Date:  2014-04       Impact factor: 0.743

3.  Sofosbuvir.

Authors:  Dennis J Cada; Jasen Cong; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-05

Review 4.  Direct-Acting Antiviral Agents for Hepatitis C Virus Infection-From Drug Discovery to Successful Implementation in Clinical Practice.

Authors:  Christopher Dietz; Benjamin Maasoumy
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

5.  Hepatitis C virus-induced prion protein expression facilitates hepatitis C virus replication.

Authors:  Huixia Zhang; Shanshan Gao; Rongjuan Pei; Xinwen Chen; Chaoyang Li
Journal:  Virol Sin       Date:  2017-10-25       Impact factor: 4.327

6.  Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment.

Authors:  Axel C Mühlbacher; John F P Bridges; Susanne Bethge; Ch-Markos Dintsios; Anja Schwalm; Andreas Gerber-Grote; Matthias Nübling
Journal:  Eur J Health Econ       Date:  2016-02-04

Review 7.  Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications.

Authors:  Lisa Sandmann; Benjamin Schulte; Michael P Manns; Benjamin Maasoumy
Journal:  Visc Med       Date:  2019-05-21

8.  Comprehensive phenotyping of regulatory T cells after liver transplantation.

Authors:  Anna Gronert Álvarez; Paraskevi Fytili; Pothakamuri V Suneetha; Anke R M Kraft; Christin Brauner; Jerome Schlue; Till Krech; Frank Lehner; Christoph Meyer-Heithuis; Elmar Jaeckel; Juergen Klempnauer; Michael P Manns; Markus Cornberg; Heiner Wedemeyer
Journal:  Liver Transpl       Date:  2015-01-20       Impact factor: 5.799

9.  Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data.

Authors:  Zhi-Wei Chen; Hu Li; Hong Ren; Peng Hu
Journal:  Sci Rep       Date:  2016-02-04       Impact factor: 4.379

10.  Sofosbuvir and daclatasvir.

Authors:  Marleen H M Hessel; Adam F Cohen; Robert Rissmann
Journal:  Br J Clin Pharmacol       Date:  2016-06-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.